Cancer Therapy Vol 3, page 537
Figure 5. A. Immunoreactive IL13R-!2 in HUVEC-C cells maintained in normal media. The cells, were treated with EGF (100 ng/ml) or TNF! (50 ng/ml) for 8, 24 and 48 hr. B. Immunoreactive IL13R-!2 in Western blot performed on lysates from SVGp12 cells maintained in serum-free media. The cells were treated with EGF (20 ng/ml) and TNF! (5 ng/ml) for 8, 24 and 48 hr. S+, serum containing media; S-, no serum. The lysate of G48a GBM cells was loaded for comparison.
Figure 6. A. The effect of inhibitors of the EGFR and its signaling on immunoreactive IL13R-!2 in U-251 MG cells. Cells were pretreated with AG1478 (10 µM), SB203580 (10 µM) and Wortmannin (100 ng/ml) 1h before the addition of EGF (100 ng/ml) for 24 hr. B. Cells were pre-treated with inhibitors of TK (AG 1478; 20 µM), ERK (PD 98059; 20 µM), JNK (SP 600125; 40 µM), p38 (SB 203580; 10 µM) and PI3-K (LY 294002; 10 µM) inhibitors 1h before the addition of EGF (100 ng/ml) for 24 hr.
537